Search the NeLM

Medicines A-Z
Find key information about medicines by name (prototype)
Vimovo (esomeprazole and naproxen) primary care briefing (Aug 2011 update)

Original article by: Alexandra Denby

Source: London New Drugs Group

Keywords: esomeprazole, naproxen, Vimovo, osteoarthritis, rheumatoid arthritis, NSAID, PPI

Date published: 08/08/2011 14:42

Summary
by: Alexandra Denby

This Primary Care Briefing has been produced to inform healthcare professionals in primary care of the new combination NSAID/proton pump inhibitor: naproxen/esomeprazole (Vimovo).

·  Esomeprazole-naproxen (Vimovo) combined tablet, taken twice a day, does not represent a significant therapeutic advance from existing alternatives.

·  Where a NSAID is recommended in combination with a PPI in national guidance, a PPI with the lowest acquisition cost should be chosen.

·  The place in therapy and advantages of Vimovo over existing products is unclear and the potentially high acquisition cost is not compatible with current financial constraints and QIPP programmes.

·  The use of generic naproxen twice a day and a low cost PPI once a day requires the patient to take just one additional tablet a day.

Vimovo_PCB_final_4_Aug2011.pdf

Preview your comment

Add new comment

Comment text:

Comments

There are no comments yet. You could be the first! You must be Logged In to comment.
Related evidence
1.3.5 Proton pump inhibitors
01/05/2012
AWMSG issues Final Appraisal Recommendation on use of esomeprazole (Nexium® IV) in children
14/09/2010
SMC accepts esomeprazole granules for oral solution (Nexium®) for treatment of GORD in children (restricted use)
13/07/2010
SMC accepts ketoprofen/omeprazole combination preparation (Axorid®) for the symptomatic treatment of rheumatoid arthritis, ankylosing spondylitis and osteoarthritis
10.1.1 Non-steroidal anti-inflammatory drugs
27/02/2012
Diclofenac with or without an antiemetic for acute migraine headaches in adults
08/11/2011
SMC does not recommend naproxen + esomeprazole combination product (Vimovo®)
01/08/2011
Fluid restriction and prophylactic indomethacin versus prophylactic indomethacin alone for prevention of morbidity and mortality in extremely low birth weight infants
Ankylosing spondylitis
13/09/2011
SMC accepts golimumab (Simponi®) for restricted use in the treatment of ankylosing spondylitis
24/08/2011
NICE issues guidance on golimumab for the treatment of ankylosing spondylitis (TA 233)
10/12/2009
Golimumab
Osteoarthritis
10/08/2011
SMC unable to recommend glucosamine sulphate (Dolenio®) due to non-submission
08/08/2011
SMC does not recommend glucosamine sulphate (Glusartel®) for symptoms of mild to moderate osteoarthritis of the knee
09/11/2010
SMC does not recommend glucosamine sulphate (Glusartel®) for the relief of symptoms in mild to moderate osteoarthritis of the knee
Rheumatoid Arthritis
15/05/2012
SMC accepts etanercept (Enbrel®) for restricted use in children and adolescents with polyarticular JIA
01/05/2012
AWMSG issues Final Appraisal Recommendation on use of adalimumab (Humira®) for active polyarticular juvenile idiopathic arthritis
10/04/2012
SMC does not accept tocilizumab for moderate to severe rheumatoid arthritis in patients unresponsive/ intolerant to DMARDs or TNF antagonists.
Back